Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.
A 31-year-old woman with MS presented with galactorrhea and elevated prolactin levels without pituitary pathology; both resolved following intravenous methylprednisolone treatment. This case demonstrates that MS-related hyperprolactinemia may not require dopaminergic intervention if the underlying cause is inflammatory demyelination rather than pituitary adenoma.
A 42-year-old man with relapsing-remitting MS developed severe reversible left ventricular dysfunction 24-36 hours after ocrelizumab infusion, with comprehensive cardiac investigation excluding ischemic or infectious causes. This case raises awareness of a potential rare cardiotoxic effect of ocrelizumab and underscores the need for cardiac monitoring in MS patients receiving this therapy.
This review examines autologous hematopoietic stem cell transplantation (AHSCT) as an emerging therapeutic option for patients with relapsing-remitting MS who are resistant to disease-modifying therapies, demonstrating sustained remission and lower relapse rates compared to conventional treatments. While AHSCT shows promise in preventing progression and improving neurological outcomes, results are mixed in progressive MS cases, and further research is needed to identify optimal patient selection and transplant protocols.
This study demonstrates that people with MS show measurable deficits in both perceptual timing (beat detection) and motor timing (finger-tapping consistency) compared to normative data, attributed to basal ganglia microstructural damage. These timing impairments correlate significantly with disease progression and fatigue severity, suggesting temporal processing measures could serve as objective biomarkers for MS disease activity.
Multiple sclerosis is a chronic autoimmune demyelinating disorder of the central nervous system that typically presents between ages 20-40, with higher prevalence in women and Northern European/North American populations. Current therapeutic approaches include disease-modifying immunomodulatory agents (interferons, glatiramer acetate, monoclonal antibodies, fumarates, and others) and symptomatic treatments to manage disease progression and disability.